Tag: guillain-barre syndrome market report

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Guillain-Barre Syndrome Market Forecast Highlighting Growth From $0.67 Billion To $0.82 Billion

The global market for Guillain-Barre syndrome treatments experienced robust expansion during the historical period and is projected to continue this upward trajectory, expanding from 0.64 billion in 2025 to 0.67 billion in 2026, reflecting a compound annual growth rate of 5.6%. Key factors contributing to this growth historically include enhanced awareness of autoimmune neurological disorders, the proliferation of specialized neurology units within hospitals, greater access to immunotherapies, a rise in post-infection complication cases, and improvements in critical care facilities.

The global market for Guillain-Barre syndrome treatments is poised for substantial expansion in the coming years, projecting a rise to $0.83 billion by 2030, fueled by a compound annual growth rate of 5.4%. This anticipated growth trajectory is underpinned by several key factors, including augmented financial commitments to neurological research, a heightened demand for innovative immunomodulatory treatments, the proliferation of dedicated rehabilitation services, the increasing integration of digital tools for neurological assessments, and a greater emphasis on strategies for early intervention. Significant developments expected during this forecast period encompass the broader application of intravenous immunoglobulin therapies, an increased uptake of plasma exchange procedures, a heightened focus on prompt neurological diagnoses, the expansion of specialized neurology care facilities, and more sophisticated methods for monitoring autoimmune neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

Guillain-Barre Syndrome Market Expansion Drivers: What Is Shaping Future Growth?

The escalating prevalence of immunological disorders is anticipated to fuel the expansion of the Guillain-Barré syndrome market. Such disorders arise when the body’s defense system malfunctions, either by overreacting, underperforming, or attacking its own tissues, resulting in conditions like autoimmune diseases, allergies, and immunodeficiency. Contributing factors to this increase include environmental shifts, lifestyle choices, enhanced diagnostic capabilities, and inherited predispositions. These immunological issues can precipitate Guillain-Barré syndrome by inciting an autoimmune response where the immune system erroneously targets peripheral nerves, causing inflammation and damage. For example, a July 2024 report from UNAIDS, a UN program focused on HIV/AIDS, indicated that by the close of 2022, an estimated 39.5 million individuals globally were living with HIV, with that year alone seeing 1.3 million new infections and 630,000 AIDS-related fatalities. This figure climbed to approximately 39.9 million people worldwide living with HIV in 2023. Consequently, the heightened risk associated with immunological diseases is a significant driver for the Guillain-Barré syndrome market.

The upsurge in healthcare spending is poised to stimulate the expansion of the Guillain-Barré syndrome market. Healthcare expenditure encompasses the total financial outlay for health-related services, from preventative measures to treatment and management of health conditions. This increase is largely attributable to progress in medical technology, as cutting-edge diagnostic instruments, novel treatments, and innovative therapies frequently incur greater costs, thereby driving up overall healthcare expenses. Greater investment in early detection, sophisticated immunotherapies, and robust critical care facilities, all facilitated by expanding healthcare budgets, is instrumental in improving the management of Guillain-Barré syndrome and enhancing patient prognoses. Illustrating this trend, data from the Centers for Medicare & Medicaid Services in the U.S. revealed that in 2023, health care expenditures in the United States rose by 7.5%, reaching $4.9 trillion, which translates to approximately $14,570 per person. Therefore, escalating healthcare expenditure is acting as a key impetus for the growth of the Guillain-Barré syndrome market.

Guillain-Barre Syndrome Market Segments: Where Are The Largest Growth Opportunities?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

Guillain-Barre Syndrome Market Strategic Trends: What Is Defining The Next Phase Of Growth?

An overview of the guillain-barre syndrome market reveals a strategic focus among leading corporations on pioneering novel therapeutic agents, notably monoclonal antibodies, with the dual objectives of elevating treatment effectiveness, satisfying existing clinical gaps, and broadening their competitive foothold. These engineered proteins, crafted in laboratories, are specifically designed to identify and interact with particular antigens, thereby facilitating the regulation of immune system activity and ultimately enhancing patient recovery. A notable development occurred in October 2023 when Annexon Inc., a biotechnology firm based in the United States, secured orphan drug status from the European Medicines Agency for its GBS therapeutic candidate, ANX005. This particular monoclonal antibody, which targets C1q, has shown promising early results, including demonstrated improvements in muscle strength and a decreased reliance on respiratory support compared to traditional intravenous immunoglobulin (IVIg) therapy, signifying a considerable step forward in disease management.

Guillain-Barre Syndrome Market Major Participants And Competitive Dynamics

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Access The Complete Guillain-Barre Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Guillain-Barre Syndrome Market Regional Analysis And Leading Geography

North Americawas the largest region in the guillain-barre syndrome market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Guillain-Barre Syndrome Market Forecast Highlighting Growth From $0.67 Billion To $0.82 Billion

The global market for Guillain-Barre syndrome treatments experienced robust expansion during the historical period and is projected to continue this upward trajectory, expanding from 0.64 billion in 2025 to 0.67 billion in 2026, reflecting a compound annual growth rate of 5.6%. Key factors contributing to this growth historically include enhanced awareness of autoimmune neurological disorders, the proliferation of specialized neurology units within hospitals, greater access to immunotherapies, a rise in post-infection complication cases, and improvements in critical care facilities.

The global market for Guillain-Barre syndrome treatments is poised for substantial expansion in the coming years, projecting a rise to $0.83 billion by 2030, fueled by a compound annual growth rate of 5.4%. This anticipated growth trajectory is underpinned by several key factors, including augmented financial commitments to neurological research, a heightened demand for innovative immunomodulatory treatments, the proliferation of dedicated rehabilitation services, the increasing integration of digital tools for neurological assessments, and a greater emphasis on strategies for early intervention. Significant developments expected during this forecast period encompass the broader application of intravenous immunoglobulin therapies, an increased uptake of plasma exchange procedures, a heightened focus on prompt neurological diagnoses, the expansion of specialized neurology care facilities, and more sophisticated methods for monitoring autoimmune neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

Guillain-Barre Syndrome Market Expansion Drivers: What Is Shaping Future Growth?

The escalating prevalence of immunological disorders is anticipated to fuel the expansion of the Guillain-Barré syndrome market. Such disorders arise when the body’s defense system malfunctions, either by overreacting, underperforming, or attacking its own tissues, resulting in conditions like autoimmune diseases, allergies, and immunodeficiency. Contributing factors to this increase include environmental shifts, lifestyle choices, enhanced diagnostic capabilities, and inherited predispositions. These immunological issues can precipitate Guillain-Barré syndrome by inciting an autoimmune response where the immune system erroneously targets peripheral nerves, causing inflammation and damage. For example, a July 2024 report from UNAIDS, a UN program focused on HIV/AIDS, indicated that by the close of 2022, an estimated 39.5 million individuals globally were living with HIV, with that year alone seeing 1.3 million new infections and 630,000 AIDS-related fatalities. This figure climbed to approximately 39.9 million people worldwide living with HIV in 2023. Consequently, the heightened risk associated with immunological diseases is a significant driver for the Guillain-Barré syndrome market.

The upsurge in healthcare spending is poised to stimulate the expansion of the Guillain-Barré syndrome market. Healthcare expenditure encompasses the total financial outlay for health-related services, from preventative measures to treatment and management of health conditions. This increase is largely attributable to progress in medical technology, as cutting-edge diagnostic instruments, novel treatments, and innovative therapies frequently incur greater costs, thereby driving up overall healthcare expenses. Greater investment in early detection, sophisticated immunotherapies, and robust critical care facilities, all facilitated by expanding healthcare budgets, is instrumental in improving the management of Guillain-Barré syndrome and enhancing patient prognoses. Illustrating this trend, data from the Centers for Medicare & Medicaid Services in the U.S. revealed that in 2023, health care expenditures in the United States rose by 7.5%, reaching $4.9 trillion, which translates to approximately $14,570 per person. Therefore, escalating healthcare expenditure is acting as a key impetus for the growth of the Guillain-Barré syndrome market.

Guillain-Barre Syndrome Market Segments: Where Are The Largest Growth Opportunities?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

Guillain-Barre Syndrome Market Strategic Trends: What Is Defining The Next Phase Of Growth?

An overview of the guillain-barre syndrome market reveals a strategic focus among leading corporations on pioneering novel therapeutic agents, notably monoclonal antibodies, with the dual objectives of elevating treatment effectiveness, satisfying existing clinical gaps, and broadening their competitive foothold. These engineered proteins, crafted in laboratories, are specifically designed to identify and interact with particular antigens, thereby facilitating the regulation of immune system activity and ultimately enhancing patient recovery. A notable development occurred in October 2023 when Annexon Inc., a biotechnology firm based in the United States, secured orphan drug status from the European Medicines Agency for its GBS therapeutic candidate, ANX005. This particular monoclonal antibody, which targets C1q, has shown promising early results, including demonstrated improvements in muscle strength and a decreased reliance on respiratory support compared to traditional intravenous immunoglobulin (IVIg) therapy, signifying a considerable step forward in disease management.

Guillain-Barre Syndrome Market Major Participants And Competitive Dynamics

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Access The Complete Guillain-Barre Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Guillain-Barre Syndrome Market Regional Analysis And Leading Geography

North Americawas the largest region in the guillain-barre syndrome market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Guillain-Barre Syndrome Market Forecast Highlighting Growth From $0.67 Billion To $0.82 Billion

The global market for Guillain-Barre syndrome treatments experienced robust expansion during the historical period and is projected to continue this upward trajectory, expanding from 0.64 billion in 2025 to 0.67 billion in 2026, reflecting a compound annual growth rate of 5.6%. Key factors contributing to this growth historically include enhanced awareness of autoimmune neurological disorders, the proliferation of specialized neurology units within hospitals, greater access to immunotherapies, a rise in post-infection complication cases, and improvements in critical care facilities.

The global market for Guillain-Barre syndrome treatments is poised for substantial expansion in the coming years, projecting a rise to $0.83 billion by 2030, fueled by a compound annual growth rate of 5.4%. This anticipated growth trajectory is underpinned by several key factors, including augmented financial commitments to neurological research, a heightened demand for innovative immunomodulatory treatments, the proliferation of dedicated rehabilitation services, the increasing integration of digital tools for neurological assessments, and a greater emphasis on strategies for early intervention. Significant developments expected during this forecast period encompass the broader application of intravenous immunoglobulin therapies, an increased uptake of plasma exchange procedures, a heightened focus on prompt neurological diagnoses, the expansion of specialized neurology care facilities, and more sophisticated methods for monitoring autoimmune neurological conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

Guillain-Barre Syndrome Market Expansion Drivers: What Is Shaping Future Growth?

The escalating prevalence of immunological disorders is anticipated to fuel the expansion of the Guillain-Barré syndrome market. Such disorders arise when the body’s defense system malfunctions, either by overreacting, underperforming, or attacking its own tissues, resulting in conditions like autoimmune diseases, allergies, and immunodeficiency. Contributing factors to this increase include environmental shifts, lifestyle choices, enhanced diagnostic capabilities, and inherited predispositions. These immunological issues can precipitate Guillain-Barré syndrome by inciting an autoimmune response where the immune system erroneously targets peripheral nerves, causing inflammation and damage. For example, a July 2024 report from UNAIDS, a UN program focused on HIV/AIDS, indicated that by the close of 2022, an estimated 39.5 million individuals globally were living with HIV, with that year alone seeing 1.3 million new infections and 630,000 AIDS-related fatalities. This figure climbed to approximately 39.9 million people worldwide living with HIV in 2023. Consequently, the heightened risk associated with immunological diseases is a significant driver for the Guillain-Barré syndrome market.

The upsurge in healthcare spending is poised to stimulate the expansion of the Guillain-Barré syndrome market. Healthcare expenditure encompasses the total financial outlay for health-related services, from preventative measures to treatment and management of health conditions. This increase is largely attributable to progress in medical technology, as cutting-edge diagnostic instruments, novel treatments, and innovative therapies frequently incur greater costs, thereby driving up overall healthcare expenses. Greater investment in early detection, sophisticated immunotherapies, and robust critical care facilities, all facilitated by expanding healthcare budgets, is instrumental in improving the management of Guillain-Barré syndrome and enhancing patient prognoses. Illustrating this trend, data from the Centers for Medicare & Medicaid Services in the U.S. revealed that in 2023, health care expenditures in the United States rose by 7.5%, reaching $4.9 trillion, which translates to approximately $14,570 per person. Therefore, escalating healthcare expenditure is acting as a key impetus for the growth of the Guillain-Barré syndrome market.

Guillain-Barre Syndrome Market Segments: Where Are The Largest Growth Opportunities?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

Guillain-Barre Syndrome Market Strategic Trends: What Is Defining The Next Phase Of Growth?

An overview of the guillain-barre syndrome market reveals a strategic focus among leading corporations on pioneering novel therapeutic agents, notably monoclonal antibodies, with the dual objectives of elevating treatment effectiveness, satisfying existing clinical gaps, and broadening their competitive foothold. These engineered proteins, crafted in laboratories, are specifically designed to identify and interact with particular antigens, thereby facilitating the regulation of immune system activity and ultimately enhancing patient recovery. A notable development occurred in October 2023 when Annexon Inc., a biotechnology firm based in the United States, secured orphan drug status from the European Medicines Agency for its GBS therapeutic candidate, ANX005. This particular monoclonal antibody, which targets C1q, has shown promising early results, including demonstrated improvements in muscle strength and a decreased reliance on respiratory support compared to traditional intravenous immunoglobulin (IVIg) therapy, signifying a considerable step forward in disease management.

Guillain-Barre Syndrome Market Major Participants And Competitive Dynamics

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Access The Complete Guillain-Barre Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Guillain-Barre Syndrome Market Regional Analysis And Leading Geography

North Americawas the largest region in the guillain-barre syndrome market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Guillain-Barre Syndrome Market Over The 2026–2030 Period?

The guillain-barre syndrome market size has shown strong expansion in recent years. It is forecast to grow from $0.64 billion in 2025 to $0.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.6%. Historically, this market’s development has been driven by factors such as enhanced recognition of autoimmune neurological conditions, the expansion of hospital-based neurology departments, broader availability of immunotherapy treatments, an increase in post-infectious complication cases, and improvements in critical care infrastructure.

The guillain-barre syndrome market is forecasted to achieve robust growth in the upcoming years. It is projected to expand to $0.83 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.4%. This anticipated growth is largely due to factors such as increased investments in neurology research, a rising demand for advanced immunomodulatory therapies, the expansion of specialized rehabilitation services, the growing adoption of digital neurological assessment tools, and a heightened focus on early intervention strategies. Prominent trends throughout the forecast period include the increasing application of intravenous immunoglobulin therapies, a rise in the use of plasma exchange procedures, an intensified emphasis on early neurological diagnosis, the continued expansion of specialized neurology care centers, and enhanced monitoring for autoimmune neurological disorders.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Which Factors Are Influencing The Growth Of The Guillain-Barre Syndrome Market?

The projected expansion of the guillain-barre syndrome market is anticipated to be fueled by the escalating prevalence of immunological diseases. These conditions manifest when the immune system functions improperly, either overreacting, underreacting, or being misdirected, leading to disorders such as autoimmune diseases, allergies, or immunodeficiencies. The rise in immunological diseases is attributed to factors like environmental shifts, lifestyle choices, improved diagnostic methods, and genetic predispositions. Immunological diseases can induce guillain-barré syndrome by initiating an autoimmune attack where the body’s immune system mistakenly targets peripheral nerves, causing inflammation and subsequent nerve damage. For example, a report from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, published in July 2024, stated that by the end of 2022, approximately 39.5 million people globally were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths documented that year. This figure increased to around 39.9 million people living with HIV worldwide in 2023. Consequently, the heightened risk of immunological diseases is propelling the guillain-barre syndrome market.

What Are The Different Segment Types In The Guillain-Barre Syndrome Market Segment Breakdown?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

Which Trends Are Influencing Demand In The Guillain-Barre Syndrome Market?

Leading companies in the guillain-barre syndrome market are prioritizing innovative drug development, such as monoclonal antibodies, to enhance treatment efficacy, address unmet clinical needs, and expand their market presence. Monoclonal antibodies are laboratory-engineered proteins designed to target specific antigens, helping modulate immune responses and improve therapeutic outcomes. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation by the European Medicines Agency (EMA) for its drug ANX005 for the treatment of guillain-barre syndrome (GBS). This is a monoclonal antibody targeting C1q, demonstrating early muscle strength improvements and reduced need for ventilation compared to IVIg, marking it as a significant therapeutic advancement.

Who Are The Well-Known Companies In The Guillain-Barre Syndrome Market?

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Get The Full Guillain-Barre Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Where Is The Guillain-Barre Syndrome Market Most Concentrated Geographically?

North America was the largest region in the guillain-barre syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Guillain-Barre Syndrome Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Browse Through More Reports Similar to the Global Guillain-Barre Syndrome Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Narcolepsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/narcolepsy-global-market-report

Progressive Ataxia And Weakness Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Guillain-Barre Syndrome Market Projected To Become By 2030 Based On Its 2026 Valuation?

The guillain-barre syndrome market has witnessed robust expansion in recent years. It is anticipated to increase from $0.64 billion in 2025 to $0.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This historical growth can be ascribed to improved recognition of autoimmune neurological conditions, the expansion of hospital-based neurology departments, increased availability of immunotherapy treatments, a rise in post-infectious complication cases, and better critical care infrastructure.

The guillain-barre syndrome market is expected to show robust expansion over the next few years. It is predicted to reach $0.83 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period stems from increased funding in neurology research, a rising demand for advanced immunomodulatory therapies, the expansion of specialized rehabilitation services, wider adoption of digital neurological assessment tools, and a heightened focus on early intervention strategies. Significant trends for the forecast period include the increasing utilization of intravenous immunoglobulin therapies, a rise in the adoption of plasma exchange procedures, a growing emphasis on early neurological diagnosis, the expansion of specialized neurology care centers, and enhanced monitoring of autoimmune neurological disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp

Which Market Drivers Are Supporting The Expansion Of The Guillain-Barre Syndrome Market?

The expanding threat of immunological diseases is anticipated to boost the growth of the guillain-barre syndrome market in the future. Immunological diseases are characterized by an overactive, underactive, or misdirected immune system, leading to conditions such as autoimmune disorders, allergies, or immunodeficiencies. These diseases are on the rise due to factors like environmental shifts, lifestyle choices, enhanced diagnostic methods, and genetic predispositions. Immunological diseases can lead to guillain-barré syndrome by initiating an autoimmune reaction where the body’s immune system mistakenly targets peripheral nerves, resulting in inflammation and nerve damage. For instance, in July 2024, a report from the Switzerland-based Joint United Nations Programme on HIV/AIDS (UNAIDS) indicated that by the close of 2022, approximately 39.5 million people globally were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths recorded that year. In 2023, the worldwide population living with HIV grew to around 39.9 million. Hence, the increasing prevalence of immunological diseases is propelling the guillain-barre syndrome market.

What Segment Groups Are Identified Within The Guillain-Barre Syndrome Market?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

What Industry Trends Are Redefining The Guillain-Barre Syndrome Market?

Major companies operating in the guillain-barre syndrome market are prioritizing the development of innovative drugs, such as monoclonal antibodies, to boost treatment efficacy, address unmet clinical requirements, and expand their market presence. Monoclonal antibodies are proteins engineered in laboratories designed to target specific antigens, which helps in modulating immune responses and improving therapeutic outcomes. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the European Medicines Agency (EMA) for its drug ANX005 for the treatment of guillain-barre syndrome (GBS). This drug is a monoclonal antibody specifically targeting C1q, which has shown early improvements in muscle strength and a reduced need for ventilation compared to IVIg, thus representing a significant therapeutic advancement.

Which Companies Hold Significant Positions In The Guillain-Barre Syndrome Market?

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Read the full guillain-barre syndrome market report here:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

How Is The Guillain-Barre Syndrome Market Distributed Across Key Geographic Regions?

North America was the largest region in the guillain-barre syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Guillain-Barre Syndrome Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21198&type=smp

Browse Through More Reports Similar to the Global Guillain-Barre Syndrome Market 2026, By The Business Research Company

Narcolepsy Global Market Report

https://www.thebusinessresearchcompany.com/report/narcolepsy-global-market-report

Progressive Ataxia And Weakness Disorders Global Market Report

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Rare Neurological Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model